Ysios Capital, a European life sciences venture capital firm, CataloniaBio & HealthTech member, announced that it has appointed Thomas Harth as Principal. Thomas will be responsible for sourcing and evaluating investment opportunities. As Principal, he will also represent Ysios as member of the board of directors of its portfolio companies.

Thomas holds a master’s degree in Bioengineering and Applied Economics, both from the University of Ghent. Previously, Thomas was Senior Associate at Gimv within the Health & Care team working out of the Antwerp office. He was focused on early-stage Life Sciences investments. Thomas co-led the investments in Anjarium biosciences and Kinaset Therapeutics and was involved with portfolio companies Fire1, ONWARD (Euronext - ONWD), Biotalys (Euronext - BTLS), JenaValve, and Breath Therapeutics (sold to Zambon).

“Attracting international talent is key to building a diverse and skilled team able to identify pioneering science worldwide and transform capital into medical breakthroughs.” comments Joël Jean-Mairet, Managing Partner at Ysios Capital.

After a very active 2021, closing  an oversubscribed €216M fund, 3 NASDAQ IPOs, and  Sanifit’s landmark acquisition by Vifor Pharma, Ysios Capital is now focused on managing its portfolio companies as well as completing the portfolio of Ysios BioFund III.

Photo: Thomas Hart